Trials / Unknown
UnknownNCT05724355
CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Dalpiciclib Combined With Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dalpiciclib Isetionate Tablets, Camrelizumab | Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W. |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2023-10-01
- Completion
- 2024-10-01
- First posted
- 2023-02-13
- Last updated
- 2023-02-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05724355. Inclusion in this directory is not an endorsement.